Physician profile
Stephen Weimer
NPI 1548354848
$770.47
in general payments reported to CMS, 2019-2025
15 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.02 · 2020: $44.47 · 2021: $135 · 2022: $114 · 2023: $120 · 2024: $149 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $167.01 | 2020-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Pfizer INC. | $149.91 | 2019-2024 | |
| Sk Life Science, INC. | $95.37 | 2021 | |
| Sobi, INC | $68.86 | 2019-2023 | |
| Sanofi Pasteur INC. | $65.32 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $37.32 | 2025 | |
| Cipher Pharmaceuticals US LLC | $33.63 | 2025 | Natroba, Spinosad |
| Regeneron Healthcare Solutions, INC. | $25.14 | 2024 | Dupixent |
| Cranial Technologies, INC | $22.19 | 2025 | Doc Band |
| Seqirus USA INC | $22.03 | 2025 | Flucelvax |
| Glaxosmithkline, LLC. | $19.92 | 2022 | |
| Millicent US INC | $17.41 | 2025 | Femlyv |
| Phadia US INC. | $17.28 | 2023 | Immunocap |
| Tris Pharma INC | $15.31 | 2025 | Onyda Xr |
| Azurity Pharmaceuticals, INC. | $13.77 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Weimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.